Results 71 to 80 of about 1,107,201 (376)

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

open access: yesMolecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son   +13 more
wiley   +1 more source

Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization

open access: yesnpj Vaccines
In August 2023, FDA approved Abrysvo for active immunization of pregnant individuals at 32 through 36 weeks gestational age to prevent lower respiratory tract disease (LRTD), including severe LRTD, caused by respiratory syncytial virus (RSV) in infants ...
Yugenia K. Hong-Nguyen   +4 more
doaj   +1 more source

ASSESSMENT OF MOUSE EMBRYO VIABILITY BY ESTERASIC ACTIVITY DETECTION

open access: yesScientific Papers Animal Science and Biotechnologies, 2023
In order to evaluate the esterasic activity within the viable embryos we used the Fluorescein diacetate (FDA) staining test. For staining was used a 0.5 mg/ml FDA stock solution. The embryos were recovered at 48 hours post coitus from superovulated Swiss
ALEXANDRA BOLEMAN   +3 more
doaj  

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

An efficient adaptive frequency sampling scheme for large-scale transient boundary element analysis

open access: yes, 2015
The frequency-domain approach (FDA) to transient analysis of the boundary element method, although is appealing for engineering applications, is computationally expensive.
Rong, Junjie   +3 more
core   +2 more sources

The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications

open access: yesClinical pharmacology and therapy, 2021
The US Food and Drug Administration (FDA) is open to accepting real‐world evidence (RWE) to support its assessment of medical products. However, RWE stakeholders lack a shared understanding of FDA’s evidentiary expectations for the use of RWE in ...
C. Purpura   +4 more
semanticscholar   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Valuation implications of pharmaceutical companies' R&D regulatory approval notifications [PDF]

open access: yes, 2013
This paper examines shareholder wealth effects surrounding applications to, and approvals by, the United States Food and Drug Administration (FDA) for firms listed on the New York (NYSE) and London (LSE) stock exchanges.
Hamill, P.A., McIlkenny, P., Opong, K.K.
core   +1 more source

Home - About - Disclaimer - Privacy